Compare DexCom, Inc. (DXCM) vs Intel Corp (INTC) Price & Performance

DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.

The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.

Intel (INTC) trades at $97.99, down 9.07% on the day, reflecting sector-wide pressure from Micron's China competition concerns. Despite recent earnings beats, the stock shows negative profitability with a net margin of -5.9% and elevated P/E of 904.17. Technical indicators are bearish, with support at $95 and resistance at $107. Positive news includes Jim Cramer's endorsement and ASML's milestone in chipmaking technology, but cash flow trends show heavy investing outflows.

Outlook: Intel faces near-term execution risks in AI competition and PC demand, but analyst consensus targets $107.55 with 37% buy ratings. Key catalysts are Q2 earnings on July 23 and AI adoption progress. Risks include margin pressure and high debt, though liquidity remains strong with $22.1B cash.